88 related articles for article (PubMed ID: 21838788)
1. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate.
Joerger M; Ferreri AJ; Krähenbühl S; Schellens JH; Cerny T; Zucca E; Huitema AD
Br J Clin Pharmacol; 2012 Feb; 73(2):240-7. PubMed ID: 21838788
[TBL] [Abstract][Full Text] [Related]
2. Urine volume to hydration volume ratio is associated with pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma.
Isono T; Hira D; Morikochi A; Fukami T; Ueshima S; Nozaki K; Terada T; Morita SY
Pharmacol Res Perspect; 2021 Dec; 9(6):e00883. PubMed ID: 34664791
[TBL] [Abstract][Full Text] [Related]
3. Comparison of differing dose levels of methotrexate for patients with primary central nervous system lymphoma.
Schrum DP; Moorman MT; Li Z; Dillon M; Peters KB; McKinney M; Patel MP
J Oncol Pharm Pract; 2024 Apr; 30(3):513-518. PubMed ID: 37198894
[TBL] [Abstract][Full Text] [Related]
4. Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma.
Haran A; Even-Zohar NG; Haran M; Lebel E; Aumann S; Shaulov A; Gatt M; Nachmias B
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):187-193.e1. PubMed ID: 38008594
[TBL] [Abstract][Full Text] [Related]
5. Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia.
Reiss SN; Buie LW; Adel N; Goldman DA; Devlin SM; Douer D
Ann Hematol; 2016 Dec; 95(12):2009-2015. PubMed ID: 27542957
[TBL] [Abstract][Full Text] [Related]
6. Understanding hemoglobin contribution to high-dose methotrexate disposition-population pharmacokinetics in pediatric patients with hematological malignancies.
Škorić B; Jovanović M; Kuzmanović M; Miljković B; Vučićević K
Eur J Clin Pharmacol; 2024 May; 80(5):697-705. PubMed ID: 38347227
[TBL] [Abstract][Full Text] [Related]
7. Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.
Benz-de Bretagne I; Zahr N; Le Gouge A; Hulot JS; Houillier C; Hoang-Xuan K; Gyan E; Lissandre S; Choquet S; Le Guellec C
Br J Clin Pharmacol; 2014 Aug; 78(2):329-42. PubMed ID: 24433481
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a model to predict acute kidney injury following high-dose methotrexate in patients with lymphoma.
Rice ML; Barreto EF; Rule AD; Martin CE; Truong HL; Mara KC; Kashani KB; Thompson CA; Witzig TE; Barreto JN
Pharmacotherapy; 2024 Jan; 44(1):4-12. PubMed ID: 37926860
[TBL] [Abstract][Full Text] [Related]
9. Risk factors associated with high-dose methotrexate induced toxicities.
Li W; Mo J; Yang Z; Zhao Z; Mei S
Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):263-274. PubMed ID: 38501267
[TBL] [Abstract][Full Text] [Related]
10. Access to Methotrexate Monitoring in Latin America: A Multicountry Survey of Supportive Care Capacity.
Villanueva G; Lowe J; Tentoni N; Taluja A; Villarroel M; Narváez CE; León SA; Valencia Libreros DL; Gonzalez Suárez N; Mikkelsen TS; Howard SC
Pediatr Hematol Oncol; 2024; 41(2):135-149. PubMed ID: 37865916
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic analyses of methotrexate in pediatric patients: a systematic review.
Cheng Y; Zhang Y; Zhang Y; Liu M; Zhao L
Eur J Clin Pharmacol; 2024 Jul; 80(7):965-982. PubMed ID: 38498098
[TBL] [Abstract][Full Text] [Related]
12. Uptake of methotrexate linked to an anti-EL4-lymphoma antibody by EL4 cells.
Uadia P; Blair AH; Ghose T
Cancer Immunol Immunother; 1983; 16(2):127-9. PubMed ID: 6559102
[TBL] [Abstract][Full Text] [Related]
13. External Evaluation of Population Pharmacokinetic Models for High-Dose Methotrexate in Adult Patients with Hematological Tumors.
Chen S; Huang L; Huang W; Zheng Y; Shen L; Liu M; Chen W; Wu X
J Clin Pharmacol; 2024 Apr; 64(4):437-448. PubMed ID: 38081138
[TBL] [Abstract][Full Text] [Related]
14. Diurnal intraocular pressure fluctuation and its risk factors in angle-closure and open-angle glaucoma.
Srinivasan S; Choudhari NS; Baskaran M; George RJ; Shantha B; Vijaya L
Eye (Lond); 2016 Mar; 30(3):362-8. PubMed ID: 26563660
[TBL] [Abstract][Full Text] [Related]
15. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing methotrexate pharmacokinetics highlight the need for individualized dose adjustment: a systematic review.
Yang Y; Liu Z; Chen J; Wang X; Jiao Z; Wang Z
Eur J Clin Pharmacol; 2024 Jan; 80(1):11-37. PubMed ID: 37934204
[TBL] [Abstract][Full Text] [Related]
17. Clinical decision support for chemotherapy-induced neutropenia using a hybrid pharmacodynamic/machine learning model.
Hughes JH; Tong DMH; Burns V; Daly B; Razavi P; Boelens JJ; Goswami S; Keizer RJ
CPT Pharmacometrics Syst Pharmacol; 2023 Nov; 12(11):1764-1776. PubMed ID: 37503916
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic drug monitoring for cytotoxic anticancer drugs: Principles and evidence-based practices.
Smita P; Narayan PA; J K; Gaurav P
Front Oncol; 2022; 12():1015200. PubMed ID: 36568145
[TBL] [Abstract][Full Text] [Related]
19. High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors.
DeAtkine AB; Abdelrashid M; Tucker Z; Mehta A; Markert JM; Kim J; Fiveash JB; Oster RA; Lobbous M; Nabors LB
J Neurooncol; 2022 May; 158(1):33-40. PubMed ID: 35441948
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
